Cochrane Review Group
Musculoskeletal
143 systematic reviews in Musculoskeletal ask 1,956 questions. 28.4% have no studies to answer them, 13% rest on very low certainty evidence and 24.8% reach moderate or high certainty.
Reviews
143
Questions
1,956
current versions
No studies
28.4%
Moderate or high
24.8%
No studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Methotrexate vs placebo Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Treatment responsea · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Pain · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Participant global assessment of well‐being · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Serious adverse events(12 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | Very low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Sustained clinically inactive diseasec · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Pain · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Sustained clinically inactive diseasec · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 143
Methotrexate for juvenile idiopathic arthritis
CochraneSoF table
24 questions
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
CochraneSoF table
12 questions
Manual therapy and exercise for lateral elbow pain
CochraneSoF table
14 questions
Cryotherapy following total knee replacement
CochraneSoF table
7 questions
The McKenzie method for (sub)acute non‐specific low back pain
CochraneSoF table
15 questions
Calcium and vitamin D for increasing bone mineral density in premenopausal women
CochraneSoF table
21 questions
Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon
CochraneSoF table
7 questions
Exercise as adjunctive therapy for systemic lupus erythematosus
CochraneSoF table
21 questions
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
CochraneSoF table
12 questions
Exercise for acutely hospitalised older medical patients
CochraneSoF table
28 questions
Foot orthoses for treating paediatric flat feet
CochraneSoF table
52 questions
Mobility training for increasing mobility and functioning in older people with frailty
CochraneSoF table
12 questions
Stem cell transplantation for systemic sclerosis
CochraneSoF table
21 questions
Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee
CochraneSoF table
14 questions
Antidepressants for hip and knee osteoarthritis
CochraneSoF table
7 questions
Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears)
CochraneSoF table
7 questions
Colchicine for acute gout
CochraneSoF table
28 questions
Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain
CochraneSoF table
7 questions
Interventions for tophi in gout
CochraneSoF table
24 questions
Non‐steroidal anti‐inflammatory drugs for acute gout
CochraneSoF table
21 questions
Dietary supplements for chronic gout
CochraneSoF table
14 questions
Belimumab for systemic lupus erythematosus
CochraneSoF table
7 questions
Autologous blood and platelet‐rich plasma injection therapy for lateral elbow pain
CochraneSoF table
7 questions
Kinesio taping for rotator cuff disease
CochraneSoF table
14 questions
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger
CochraneSoF table
7 questions